Navigation Links
People Exposed To Lead Likely To Die From Brain Cancer

According to University of Rochester Medical Center study people exposed to lead on the job are 50 percent more likely to die from brain cancer than people who are not// exposed. The study author Edwin van Wijngaarden, Ph.D., said the study provides further evidence that widespread environmental risk factors such as lead must be explored. The study, which might be the largest study ever to find a lead-cancer link, was based on the information from the U.S. Census Bureau and the National Death Index.

More than 18,000 brain and spinal cord tumors will be diagnosed in the United States this year. Yet little is known about what causes brain cancer; the only established risk factor is radiation, according to the American Cancer Society.

"If we are able to help explain the cause of even 1 or 2 percent of the total number of cases, that's important," said van Wijngaarden, an assistant professor and epidemiologist in the Department of Community and Preventive Medicine at the University of Rochester.

Published in the Sept. 1, 2006, issue of the International Journal of Cancer, the study computed the risk estimates for lead exposure and brain cancer from a census sample of 317,968 people who reported their occupations between 1979 and 1981. Van Wijngaarden was looking for evidence of an exposure-response trend, or a rise in cancer incidence or mortality associated with an exposure to a toxic substance. The goal among researchers who do this type of investigation is to identify preventable, environmental risk factors that might cause the gene mutations that lead to cancer.

Each occupation was classified into categories established by the National Cancer Institute. The NCI job matrix for lead is designed to estimate the likelihood of exposure and the intensity of exposure. It rates each occupation on a scale from zero (no exposure) to three (high exposure).

Gas station attendants from the 1970s and early 1980s, f
'"/>




Page: 1 2

Related medicine news :

1. Bad News for Short People
2. New hope on the Horizon for People Wishing to Quit Smoking
3. Prescription Drug - Helps People Stop Smoking
4. More People Seeking Treatment for Depression
5. Pain Common in People with MS
6. People with skin cancer at higher risk for other types
7. Laser Therapy Found To Help People Quit Smoking
8. Pomegranate Juice May Be The Next Best Thing For People With Heart Disease
9. New Treatment For People Allergic To Cats
10. People who fight wars may be at high risk of cardiovascular disease
11. People suffering from Alzheimer’s: can they take decisions about their treatment
Post Your Comments:
Breaking Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Bayer Consumer Care Voluntarily Recalls One Lot of Combination Package of Alka-Seltzer Plus(R) Day & Night Cold Formula Liquid Gels 2ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 1InteKrin Therapeutics Announces Appointment of Geoffrey M Parker as Chief Business Officer 51443 2Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 1Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 2Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 3Gentiva 28R 29 Health Services Schedules Second Quarter Earnings Call and Web Cast for Thursday July 30 2009 51438 4Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 1Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 51435 2
Other Medicine Technology:NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 2NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 3NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 4NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 5NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting 6Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 2Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 3Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 4Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 5Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study 6